NCT01130298

Brief Summary

Single-center, single dose, open-label study in healthy male and female volunteers to further characterize the transfer potential of Testosterone Gel 1.62% formulation.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at P25-P50 for phase_1 healthy

Timeline
Completed

Started May 2010

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2010

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

May 21, 2010

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 26, 2010

Completed
Last Updated

December 7, 2017

Status Verified

June 1, 2011

Enrollment Period

Same day

First QC Date

May 21, 2010

Last Update Submit

December 5, 2017

Conditions

Keywords

testosterone,Pharmacokineticsreplacement,therapy

Outcome Measures

Primary Outcomes (3)

  • Maximum Plasma Concentration observed (Cmax)

    Maximum plasma concentration observed (Cmax) of total testosterone

    Up to 5 days

  • Area Under the Plasma Concentration-time Curve (AUC)

    Area under the plasma concentration-time curve (AUC) of total testosterone

    Up to 5 days

  • Average Plasma Concentration observed (Cav)

    Average Plasma Concentration observed (Cav) of total testosterone

    Up to 5 days

Study Arms (1)

1

EXPERIMENTAL
Drug: Testosterone Gel 1.62%

Interventions

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • BMI between 20-35 kg/m\^2 inclusive.

You may not qualify if:

  • Males: history, current or suspected prostate or breast cancer.
  • Females: pregnant or lactating.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Stahlman J, Britto M, Fitzpatrick S, McWhirter C, Testino SA, Brennan JJ, Zumbrunnen TL. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption. Curr Med Res Opin. 2012 Feb;28(2):291-301. doi: 10.1185/03007995.2011.652732. Epub 2012 Jan 24.

Study Officials

  • Michael Miller, PharmD

    Abbott

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 21, 2010

First Posted

May 26, 2010

Study Start

May 1, 2010

Primary Completion

May 1, 2010

Study Completion

May 1, 2010

Last Updated

December 7, 2017

Record last verified: 2011-06